Dihexa 100x10mg

NOT FOR HUMAN CONSUMPTION

Dihexa is a brain-penetrant angiotensin-IV (AngIV)–derived peptide engineered for extreme metabolic stability and oral/CNS bioavailability. Unlike classical RAS drugs, Dihexa functions as a hepatocyte growth factor (HGF)–c-Met signaling potentiator: it binds HGF with high affinity and facilitates HGF–c-Met dimerization/activation, driving synaptogenesis, spine density, and plasticity-related gene expression. It is not approved for any indication; human trials are absent as of 2025.

Additional Benefits of Dihexa Now Under Investigation

2. Molecular Mechanism of Action

2.1 Receptor pharmacodynamics

• Primary: Allosteric potentiation of HGF–c-Met signaling (not a direct c-Met agonist). Dihexa binds HGF, stabilizing its active dimer → c-Met phosphorylation.

• Downstream: PI3K–Akt–mTOR (survival/translation), MAPK/ERK (plasticity), Rac1/Cdc42 (spine morphogenesis), and CREB/BDNF transcription.

• Contrast with AngIV: Native AngIV interacts with AT4/IRAP; Dihexa’s potency and plasticity effects are mainly HGF–c-Met–dependent in modern studies.

2.2 Down-stream biology

3. Pharmacokinetics

• Route: Effective orally and parenterally in rodents; CNS-penetrant.

• Stability: Protease-resistant backbone with lipophilic N-hexanoyl cap → high metabolic stability.

• Brain exposure: Detected in brain tissue after systemic dosing; duration hours with functional effects lasting days–weeks after courses in animals.

• Human PK: Unknown (no published trials).

4. Pre-clinical & Translational Evidence

• Cognition/AD: Reversal of scopolamine, Aβ, and lesion-induced deficits at very low doses; potentiates LTP and spine markers.

• TBI/PD: Functional recovery and synaptic rebuilding demonstrated in multiple injury/toxin paradigms.

• Mechanistic dependency: Genetic or pharmacologic c-Met blockade blunts Dihexa’s synaptogenic effects, supporting target engagement.

Evidence quality note: Robust rodent/in vitro data with convergent mechanisms. No peer-reviewed human studies to date; dose, safety, and efficacy in people remain unknown.

5. Emerging Clinical Interests (conceptual)

6. Safety and Tolerability

• On-target oncogenicity concern: HGF–c-Met is a proto-oncogene pathway. Chronic potentiation may promote tumor growth, invasion, or angiogenesis, especially in individuals with c-Met-driven cancers or premalignant lesions. Long-term carcinogenicity data for Dihexa are absent.

• CNS AEs (theoretical): Headache, insomnia/activation, irritability, or abnormal dreams from heightened plasticity signaling; not systematically studied.

• Cardio-metabolic/vascular: HGF can be pro-angiogenic; monitor for edema or BP changes in any future trials.

• Reproductive: Unknown effects on fetal development (HGF is morphogenic) → avoid in pregnancy conceptually.

• Drug interactions: Potential synergy/interference with mTOR modulators, antidepressants, stimulants, or anti-c-Met oncology drugs (crizotinib, capmatinib).

• Abuse/misuse risk: Grey-market “nootropic” products are unregulated; composition frequently mislabelled.

Comparative safety matrix

7. Regulatory Landscape

• Not approved by FDA/EMA/PMDA for any indication.

• Exists in patents and academic publications; no registered therapeutic product.

• Compounded/RC versions online are not quality-assured and carry unknown identity/purity.

8. Practical Take & Future Directions

• Do not self-experiment. Until GLP toxicology, carcinogenicity, full PK/PD, and phase-1 safety are completed, Dihexa should remain laboratory-only.

• Clinical trial blueprint:

  • Phase 1: SAD/MAD in healthy adults with oncology screening, cutaneous/thyroid exams, and circulating tumor DNA exploratory safety markers; qEEG/cognitive batteries for PD signals.

  • Phase 2a (MCI/early AD or post-TBI): Biomarker-anchored (functional connectivity MRI, plasma p-tau/Aβ, neurofilament light), digital cognition, and speech/eye-tracking endpoints.

  • Risk mitigation: Exclude active cancer, mandate oncologic surveillance, and cap exposure duration until risk is characterized.

• Chemistry: Explore biased c-Met potentiation, brain-selective delivery, or activity-dependent prodrugs to minimize peripheral exposure.

Selected References

• Journal of Pharmacology and Experimental Therapeutics; Neurobiology of Learning and Memory, Dihexa’s memory enhancement in rodent models and dose–response characteristics.

• Proceedings of the National Academy of Sciences; Journal of Neuroscience, HGF–c-Met–mediated synaptogenesis and downstream signaling (ERK/Akt, spine density).

• Neurotherapeutics; Alzheimer’s Research & Therapy, Synaptic rescue frameworks in AD models; plasticity gene programs (BDNF, Arc).

• Brain Research; Experimental Neurology, Traumatic brain injury recovery and neurite outgrowth data.

• Movement Disorders; Molecular Neurobiology, Parkinsonian model plasticity and behavior.

• Hearing Research; JARO, Cochlear synaptopathy protection/repair under HGF potentiation.

• Cancer Research; Nature Reviews Cancer, Biology and oncogenic potential of HGF–c-Met signaling (context for safety).